Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled trial of CC-99677 capsules in active ankylosing spondylitis
CTR20220937Phase 2Terminated
- Sponsor
- Celgene Corporation
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gamcemetinib in ankylosing spondylitis (AS), sponsored by Celgene Corporation. Started Apr 2022; status: terminated.
02
Drugs
gamcemetinib
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on CTR20220937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220937.